Lake Street lowered the firm’s price target on OptimizeRx to $15 from $17 and keeps a Buy rating on the shares. Optimize “experienced a speed bump in Q2,” but the firm is confident the company can meet its 2024 guidance, says the analyst, who lowered the firm’s price target to reflect a trimmed revenue estimate and back half skewing.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx resumed with a Buy at B. Riley
- OptimizeRx Sets Second Quarter 2024 Conference Call for August 8, 2024 at 4:30 p.m. ET
- OptimizeRx delivers AI-guided privacy-compliant platform
- OptimizeRx Delivers AI-Guided Privacy-Compliant Platform for Pharmaceutical Brand Marketing Amid Evolving Consumer Privacy Legislation
- OptimizeRx Demonstrates Measurable Script Lift for a Major Depressive Disorder Brand Targeting Physicians of Hard-to-Reach Patients